These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36519977)

  • 21. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
    Dennison SM; Stewart SM; Stempel KC; Liao HX; Haynes BF; Alam SM
    J Virol; 2009 Oct; 83(19):10211-23. PubMed ID: 19640992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.
    Sánchez-Martínez S; Lorizate M; Katinger H; Kunert R; Nieva JL
    AIDS Res Hum Retroviruses; 2006 Oct; 22(10):998-1006. PubMed ID: 17067270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular basis of the structural stability of a Top7-based scaffold at extreme pH and temperature conditions.
    Soares TA; Boschek CB; Apiyo D; Baird C; Straatsma TP
    J Mol Graph Model; 2010 Jun; 28(8):755-65. PubMed ID: 20185346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
    de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
    J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.
    Crespillo S; Casares S; Mateo PL; Conejero-Lara F
    J Biol Chem; 2014 Jan; 289(2):594-9. PubMed ID: 24302742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
    Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
    J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
    Serrano S; Araujo A; Apellániz B; Bryson S; Carravilla P; de la Arada I; Huarte N; Rujas E; Pai EF; Arrondo JLR; Domene C; Jiménez MA; Nieva JL
    J Biol Chem; 2014 Mar; 289(10):6565-6580. PubMed ID: 24429284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
    Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
    PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotin-painted proteins have thermodynamic stability switched by kinetic folding routes.
    Freitas FC; Maldonado M; Oliveira Junior AB; Onuchic JN; Oliveira RJ
    J Chem Phys; 2022 May; 156(19):195101. PubMed ID: 35597640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint.
    Ho J; MacDonald KS; Barber BH
    Vaccine; 2002 Jan; 20(7-8):1169-80. PubMed ID: 11803079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drift-diffusion (DrDiff) framework determines kinetics and thermodynamics of two-state folding trajectory and tunes diffusion models.
    Freitas FC; Lima AN; Contessoto VG; Whitford PC; Oliveira RJ
    J Chem Phys; 2019 Sep; 151(11):114106. PubMed ID: 31542001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.